Kevin Outterson, JD, LLM
Professor of Law and N. Neal Pike Scholar
Boston University School of Law
Dept of Health and Disability Law

LLM, University of Cambridge
JD, Northwestern University School of Law




Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Associate Professor of Health Law, Ethics & Human Rights
Boston University School of Public Health
Health Law, Policy & Management
Center for Health Law, Ethics & Human Rights

Executive Director of CARB-X
Boston University School of Law
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)




VALUE-Dx
04/01/2019 - 03/31/2023 (Subcontract PI)
University of Antwerp European Commission


Accelerating the Development of innovative Preventive Approaches to Combat AMR
01/01/2019 - 12/31/2022 (PI)
The German Federal Ministry of Education and Research


RESTRICTED: Accelerating the Development of Innovative Preventive Approaches to Combat AMR
01/01/2019 - 12/31/2022 (PI)
The German Federal Ministry of Education and Research


Accelerating the Development ofinnovative Preventive Approaches to Combat AMR
05/18/2018 - 05/31/2022 (PI)
Bill and Melinda Gates Foundation


CARB-X/ UK GAMRIF
05/18/2018 - 03/31/2022 (PI)
Department of Health and Social Care


WT CARB-X Core Mgmt/Other Program Support
01/01/2019 - 07/31/2021 (PI)
Wellcome Trust


WT CARB-X PD/Acc Costs Cost-Share
04/01/2017 - 07/31/2021 (PI)
Wellcome Trust


WT CARB-X Non Awardee Costs
04/01/2017 - 07/31/2021 (PI)
Wellcome Trust


CARB-X
08/01/2016 - 07/31/2021 (PI)
HHS/Assistant Secretary for Preparedness and Response
6IDSEP160030-05-03



Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Kim W, Krause K, Zimmerman Z, Outterson K. Improving data sharing to increase the efficiency of antibiotic R&D. Nat Rev Drug Discov. 2021 Jan; 20(1):1-2. PMID: 33097914
     
  2. Minssen T, Outterson K, Rogers Van Katwyk S, Batista PHD, Chandler CIR, Ciabuschi F, Harbarth S, Kesselheim AS, Laxminarayan R, Liddell K, Osterholm MT, Price L, Hoffman SJ. Social, cultural and economic aspects of antimicrobial resistance. Bull World Health Organ. 2020 Dec 01; 98(12):823-823A. PMID: 33293739
     
  3. Morel CM, Alm RA, Årdal C, Bandera A, Bruno GM, Carrara E, Colombo GL, de Kraker MEA, Essack S, Frost I, Gonzalez-Zorn B, Goossens H, Guardabassi L, Harbarth S, Jørgensen PS, Kanj SS, Kostyanev T, Laxminarayan R, Leonard F, Hara GL, Mendelson M, Mikulska M, Mutters NT, Outterson K, Bano JR, Tacconelli E, Scudeller L. A one health framework to estimate the cost of antimicrobial resistance. Antimicrob Resist Infect Control. 2020 11 26; 9(1):187. PMID: 33243302
     
  4. Kirchhelle C, Atkinson P, Broom A, Chuengsatiansup K, Ferreira JP, Fortané N, Frost I, Gradmann C, Hinchliffe S, Hoffman SJ, Lezaun J, Nayiga S, Outterson K, Podolsky SH, Raymond S, Roberts AP, Singer AC, So AD, Sringernyuang L, Tayler E, Rogers Van Katwyk S, Chandler CIR. Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy. BMJ Glob Health. 2020 09; 5(9). PMID: 32967980
     
  5. Rex JH, Outterson K. Antibacterial R&D at a crossroads: We've pushed as hard as we can … now we need to start pulling! Clin Infect Dis. 2020 Jun 25. PMID: 32584949
     
  6. Outterson K, Rex JH. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. Transl Res. 2020 06; 220:182-190. PMID: 32165059
     
  7. Laxminarayan R, Van Boeckel T, Frost I, Kariuki S, Khan EA, Limmathurotsakul D, Larsson DGJ, Levy-Hara G, Mendelson M, Outterson K, Peacock SJ, Zhu YG. The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. Lancet Infect Dis. 2020 04; 20(4):e51-e60. PMID: 32059790
     
  8. Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. Clin Infect Dis. 2020 Jan 30. PMID: 31999818
     
  9. Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, Sumpradit N. Antibiotic development - economic, regulatory and societal challenges. Nat Rev Microbiol. 2020 05; 18(5):267-274. PMID: 31745330
     
  10. Theuretzbacher U, Outterson K, Engel A, Karlén A. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020 05; 18(5):275-285. PMID: 31745331
     
Showing 10 of 79 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 79 publications over 20 distinct years, with a maximum of 9 publications in 2011

YearPublications
19981
20031
20041
20058
20064
20071
20083
20098
20105
20119
20123
20132
20141
20155
20166
20174
20183
20196
20207
20211
Contact for Mentoring:

765 Commonwealth Ave
Boston MA 02215
Google Map


Outterson's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_